For clinicians and informed patients tracking stroke treatment research, the integrity of trial design amendments carries real weight — a mid-study protocol change can either strengthen a trial's validity or introduce subtle bias that distorts conclusions. This exchange in JAMA surfaces a methodological debate worth understanding in the context of acute ischemic stroke intervention research.
The correspondence concerns a randomized trial evaluating intra-arterial alteplase administered following successful mechanical thrombectomy in acute ischemic stroke. The authors' reply addresses criticism of a primary outcome amendment made on February 10, 2025 — after 283 patients had enrolled, with 214 having completed or become eligible for 90-day follow-up. The investigators defend the change by citing the absence of interim analyses and confirming that no treatment-group outcome data were accessible at the time, asserting the revision was driven by evolving evidence and the established use of blinded modified Rankin Scale (mRS) assessments rather than by any unblinded results.
Mid-trial outcome amendments are one of the more contested areas in clinical trial methodology. Regulatory and statistical guidelines generally require that primary endpoint changes be pre-specified or, at minimum, conducted without access to unblinded accumulating data — the condition the authors claim was met here. However, even well-intentioned amendments raise questions about outcome harvesting, where researchers consciously or unconsciously select metrics more likely to yield significant results. The modified Rankin Scale, while standard in stroke trials, has known sensitivity to how disability thresholds are defined, making endpoint framing consequential. This reply does not resolve those concerns definitively; it provides the trial team's rationale. Whether the amendment strengthens or weakens confidence in eventual results will depend on final data transparency and independent statistical review. This is an incremental methodological clarification, not a clinical finding — its significance lies in what it signals about trial conduct standards in stroke intervention research.